This is a concern, especially since the benefits of anti-platelet and lipid lowering therapy in patients with type 2 diabetes have clearly been established in earlier large randomized clinical trials [17???19].A high proportion of patients in this study had poor glycaemic control, an expected finding since this was a selection criterio